<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Primary Antiphospholipid Protein Syndrome (PAPS) is characterised by venous and/or arterial thromboses and recurrent foetal loss, in the presence of the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">Anticoagulant</z:chebi> (LA), elevated antibodies to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (ACA) or both </plain></SENT>
<SENT sid="1" pm="."><plain>This investigation evaluates the relation between the PAPS and <z:chebi fb="46" ids="15035">Retinal</z:chebi> Vein Occlusion (RVO) </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-eight consecutive patients with RVO were screened for ACA and LA </plain></SENT>
<SENT sid="3" pm="."><plain>PAPS was present in 16 (33%) of the patients </plain></SENT>
<SENT sid="4" pm="."><plain>Our results suggest that testing Antiphospholipid-Protein Antibodies (<z:chebi fb="21" ids="53713">APA</z:chebi>) may be useful in these patients, together with the assessment of other vascular risk factors </plain></SENT>
</text></document>